SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 56,500 shares, a growth of 134.4% from the October 31st total of 24,100 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 29,800 shares, the days-to-cover ratio is presently 1.9 days.

SOPHiA GENETICS Trading Up 0.6 %

Shares of SOPH stock traded up $0.02 during mid-day trading on Thursday, reaching $3.27. 13,455 shares of the stock traded hands, compared to its average volume of 65,420. The company has a market cap of $213.79 million, a price-to-earnings ratio of -3.07 and a beta of 1.03. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. The stock’s fifty day simple moving average is $3.55 and its two-hundred day simple moving average is $4.08. SOPHiA GENETICS has a 1-year low of $2.70 and a 1-year high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. During the same quarter in the prior year, the business earned ($0.21) earnings per share. On average, research analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Morgan Stanley downgraded SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $10.00 to $5.00 in a research note on Wednesday, August 7th. Royal Bank of Canada dropped their price objective on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SOPH. Banque Cantonale Vaudoise increased its stake in shares of SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after buying an additional 9,000 shares during the period. Green Alpha Advisors LLC bought a new stake in SOPHiA GENETICS in the third quarter valued at approximately $79,000. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after purchasing an additional 23,000 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares during the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.